Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Injectable hydrogel-based localized delivery of IDO-galectin-3 mitigates neuroinflammation and promotes neuronal sparing after spinal cord contusion in rats.

Journal of materials chemistry. B·2026
Same author

A single intra-articular injection of IDO-Gal3 shifts synovial fluid metabolic profiles for up to six weeks in male rats with knee instability.

Biochimie·2026
Same author

Injectable hydrogel-based localized delivery of IDO-galectin-3 mitigates neuroinflammation and promotes neuronal sparing after spinal cord contusion in rats.

Journal of materials chemistry. B·2026
Same author

Indoleamine 2,3-dioxygenase-galectin-3 fusion protein remodels inflammatory and fibrotic programs, ameliorating imiquimod-induced psoriasis.

npj biomedical innovations·2025
Same author

Gut commensal bacteria-derived polysaccharide sub-micron particles induce antigen-specific, tolerogenic responses.

Frontiers in immunology·2025
Same author

Engineering an indoleamine 2,3-dioxygenase immunotherapy <i>via</i> selective cysteine-to-serine mutations.

Molecular systems design & engineering·2025

Related Experiment Video

Updated: May 20, 2026

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

Microparticle surface modifications targeting dendritic cells for non-activating applications.

Jamal S Lewis1, Toral D Zaveri, Charles P Crooks

  • 1J Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611-6131, USA.

Biomaterials
|July 17, 2012
PubMed
Summary
This summary is machine-generated.

Researchers optimized poly (d lactide-co-glycolide) microparticles (MPs) for non-activating delivery to dendritic cells (DCs). P-D2 peptide functionalization enhanced DC antigen presentation and in vivo translocation, informing vaccine design for autoimmune diseases.

More Related Videos

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

Optimized Protocol for Efficient Transfection of Dendritic Cells without Cell Maturation
08:08

Optimized Protocol for Efficient Transfection of Dendritic Cells without Cell Maturation

Published on: July 8, 2011

Related Experiment Videos

Last Updated: May 20, 2026

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo
10:35

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

Optimized Protocol for Efficient Transfection of Dendritic Cells without Cell Maturation
08:08

Optimized Protocol for Efficient Transfection of Dendritic Cells without Cell Maturation

Published on: July 8, 2011

Area of Science:

  • Biomaterials Science
  • Immunology
  • Drug Delivery Systems

Background:

  • Microparticulate systems are emerging for targeted immunotherapy via dendritic cell (DC) delivery.
  • Optimization of non-activating DC-targeting microparticle delivery systems remains a challenge.
  • Current strategies often lack specific targeting or induce unwanted immune activation.

Purpose of the Study:

  • To investigate the optimization of poly (d lactide-co-glycolide) microparticles (MPs) for non-stimulatory DC targeting.
  • To evaluate the in vitro and in vivo efficacy of modified MPs for enhanced DC interaction and function.
  • To inform the design of novel polymeric microparticulate vaccines for autoimmune diseases.

Main Methods:

  • Surface modification of MPs with DC receptor targeting ligands: anti-CD11c, anti-DEC-205 antibodies, and P-D2, RGD peptides.
  • Assessment of MP toxicity and activation potential in vitro.
  • Evaluation of DC uptake, antigen presentation, and in vivo immune cell translocation.
  • Utilizing poly (d lactide-co-glycolide) as the microparticle base material.

Main Results:

  • Modified MPs exhibited no toxicity or activation.
  • Anti-DEC-205 antibody, anti-CD11c antibody, and P-D2 peptide modifications improved DC uptake in vitro.
  • P-D2 peptide functionalization significantly enhanced DC antigen presentation both immediately and later.
  • P-D2 peptide and anti-CD11c antibody modified MPs showed increased in vivo translocation by DCs and MΦs, with P-D2 being most effective.

Conclusions:

  • Surface functionalization of poly (d lactide-co-glycolide) microparticles can achieve non-activating targeting of dendritic cells.
  • P-D2 peptide modification represents a promising strategy for enhancing DC antigen presentation and immune cell trafficking.
  • These findings provide a foundation for developing advanced polymeric microparticle-based vaccines, particularly for autoimmune conditions.